Tourmaline Bio Statistics
Share Statistics
Tourmaline Bio has 25.64M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 25.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 454 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 1.56M, so 6.07% of the outstanding shares have been sold short.
| Short Interest | 1.56M |
| Short % of Shares Out | 6.07% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 6.39 |
Valuation Ratios
The PE ratio is -2.95 and the forward PE ratio is -7.34.
| PE Ratio | -2.95 |
| Forward PE | -7.34 |
| PS Ratio | 0 |
| Forward PS | 56.1 |
| PB Ratio | 0.61 |
| P/FCF Ratio | -4.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Tourmaline Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 41.76, with a Debt / Equity ratio of 0.
| Current Ratio | 41.76 |
| Quick Ratio | 41.76 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.2 |
| Cash Flow / Debt | -67.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -22.1%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -22.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -569.24K |
| Employee Count | 74 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 9.45% in the last 52 weeks. The beta is 0, so Tourmaline Bio 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 9.45% |
| 50-Day Moving Average | 26.04 |
| 200-Day Moving Average | 20.99 |
| Relative Strength Index (RSI) | 37.28 |
| Average Volume (20 Days) | 235.39K |
Income Statement
In the last 12 months, Tourmaline Bio had revenue of $0 and earned -$42.12M in profits. Earnings per share was $-8.87.
| Revenue | 0 |
| Gross Profit | -33.00K |
| Operating Income | -45.41M |
| Net Income | -42.12M |
| EBITDA | -45.38M |
| EBIT | - |
| Earnings Per Share (EPS) | -8.87 |
Balance Sheet
The company has $140.73M in cash and $415.00K in debt, giving a net cash position of $140.31M.
| Cash & Cash Equivalents | 140.73M |
| Total Debt | 415.00K |
| Net Cash | 140.31M |
| Retained Earnings | -62.05M |
| Total Assets | 328.45M |
| Working Capital | 286.50M |
Cash Flow
In the last 12 months, operating cash flow was -$28.08M and capital expenditures -$56.00K, giving a free cash flow of -$28.14M.
| Operating Cash Flow | -28.08M |
| Capital Expenditures | -56.00K |
| Free Cash Flow | -28.14M |
| FCF Per Share | -5.93 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TRML does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -40.52% |
| FCF Yield | -5.01% |
Analyst Forecast
The average price target for TRML is $50, which is 128.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $50 |
| Price Target Difference | 128.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Oct 20, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 45.97 |
| Piotroski F-Score | 3 |